As it kicks off its annual Specialty Pharmacy Summit (Las Vegas, Apr. 29-May 2), Asembia has announced a new offering that provides a level of patient support to drugs that typically are not budgeted for the high-touch, high-cost services of […]
Read MoreEnvoyHealth, the independently operated subsidiary of leading specialty pharmacy, Diplomat, has added partnerships with two web-based services in the past month. Combined, the services promise to improve speed to therapy and adherence to drug regimens, in the near term, and […]
Read MoreOne thing’s for sure. There has perhaps never been a better time to be strategizing how to devise patents, distribution channels, rebates and commercial arrangements to maximize revenue or market share in the US drug market. The current hue and […]
Read MoreAccording to a report in FiercePharmaMarketing, J&J’s Janssen unit might be the first US pharma company to include price information in its TV advertising for Xarelto, a widely used blood thinner. The ads, which include a $448 list price for […]
Read MoreAfter the flurry of hype, artificial intelligence is on the rise and enabling a smarter, more efficient and more effective business. Once-scrappy experiments have now matured into high-impact enterprise applications. Many organizations, however, are still unclear about how to build […]
Read MoreLash Group, a business unit of AmerisourceBergen since 1998, was one of the pioneering firms established to provide patient-support services, sponsored by pharma companies, in the specialty-pharmaceutical arena. It currently manages over 100 drug programs, with over 1,000 associates, mostly […]
Read MoreCareMetx, a leading provider of patient support (hub) services, has announcing an alliance with Vineti, with the partnership forming the basis of a new CareMetx division, OutcomesRx. Together, the firms will develop a combination of active patient support (benefits verification, […]
Read More
Model N made its bones with the concept of revenue management: in life sciences, analyzing the elements of commercial contracts to maximize profitability and minimizing poorly executed incentive or rebate programs. Now, in a commissioned 2019 survey across its prospect […]
Read MoreNon-adherence to therapy is widely recognized as an ever-present problem in healthcare generally and the pharma industry specifically, which forgoes some $250 billion annually in lost sales. The picture is changing, somewhat, from past years, as health systems now have […]
Read MoreAs the US healthcare system continues to shift its reimbursement model from volume-based (fee for service) to value-based (fee for outcome), the landscape for specialty care is becoming increasingly complex. At the same time, a growing number of innovative specialty […]
Read More